GB Sciences, Inc. (GBLX)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -624.00 USD | 98.99% |
| 2022 | -61.66 Thousand USD | 12.52% |
| 2021 | -70.48 Thousand USD | -48.86% |
| 2020 | -47.35 Thousand USD | 94.63% |
| 2019 | -881.46 Thousand USD | -522.86% |
| 2018 | 208.45 Thousand USD | -87.93% |
| 2017 | 1.72 Million USD | 515.32% |
| 2016 | -415.97 Thousand USD | -134.85% |
| 2015 | -177.12 Thousand USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | -100.0% |
| 2006 | 1.08 Million USD | 1879.71% |
| 2005 | -60.94 Thousand USD | 0.0% |
| 2004 | - USD | -100.0% |
| 2003 | 1088.00 USD | -91.43% |
| 2002 | 12.69 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 Q1 | -624.00 USD | 0.0% |
| 2023 Q3 | - USD | 0.0% |
| 2023 Q4 | - USD | 0.0% |
| 2023 FY | -624.00 USD | 98.99% |
| 2023 Q2 | - USD | 100.0% |
| 2022 Q3 | -21.16 Thousand USD | -3.73% |
| 2022 Q4 | - USD | 100.0% |
| 2022 FY | -61.66 Thousand USD | 12.52% |
| 2022 Q1 | -20.08 Thousand USD | -17.71% |
| 2022 Q2 | -20.4 Thousand USD | -1.59% |
| 2021 Q2 | -17.73 Thousand USD | -2.17% |
| 2021 Q3 | -18.33 Thousand USD | -3.43% |
| 2021 Q4 | -17.06 Thousand USD | 6.95% |
| 2021 FY | -70.48 Thousand USD | -48.86% |
| 2021 Q1 | -17.35 Thousand USD | 96.95% |
| 2020 FY | -47.35 Thousand USD | 94.63% |
| 2020 Q1 | 59.4 Thousand USD | 198.16% |
| 2020 Q4 | -568.45 Thousand USD | 0.0% |
| 2020 Q2 | - USD | -100.0% |
| 2020 Q3 | - USD | 0.0% |
| 2019 Q2 | -685.45 Thousand USD | -339.41% |
| 2019 FY | -881.46 Thousand USD | -522.86% |
| 2019 Q1 | 286.3 Thousand USD | 121.46% |
| 2019 Q3 | -421.8 Thousand USD | 38.46% |
| 2019 Q4 | -60.51 Thousand USD | 85.65% |
| 2018 Q4 | -1.33 Million USD | -439.26% |
| 2018 Q1 | 734.71 Thousand USD | 13.01% |
| 2018 Q3 | 393.19 Thousand USD | -5.14% |
| 2018 Q2 | 414.48 Thousand USD | -43.59% |
| 2018 FY | 208.45 Thousand USD | -87.93% |
| 2017 Q3 | 886.74 Thousand USD | 5097.69% |
| 2017 Q1 | 39.09 Thousand USD | 0.0% |
| 2017 FY | 1.72 Million USD | 515.32% |
| 2017 Q4 | 650.15 Thousand USD | -26.68% |
| 2017 Q2 | -17.74 Thousand USD | -145.38% |
| 2016 FY | -415.97 Thousand USD | -134.85% |
| 2016 Q4 | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 FY | -177.12 Thousand USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2009 Q2 | 53 Thousand USD | 0.0% |
| 2009 Q3 | - USD | -100.0% |
| 2009 Q4 | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2007 Q3 | 323.89 Thousand USD | -23.96% |
| 2007 Q4 | - USD | -100.0% |
| 2007 Q2 | 425.93 Thousand USD | 77.66% |
| 2007 Q1 | 239.74 Thousand USD | 125.84% |
| 2007 FY | - USD | -100.0% |
| 2006 Q4 | 106.15 Thousand USD | -78.0% |
| 2006 Q2 | 404.43 Thousand USD | 342.11% |
| 2006 FY | 1.08 Million USD | 1879.71% |
| 2006 Q1 | 91.47 Thousand USD | 524.94% |
| 2006 Q3 | 482.55 Thousand USD | 19.32% |
| 2005 Q1 | 919.00 USD | 0.0% |
| 2005 FY | -60.94 Thousand USD | 0.0% |
| 2005 Q3 | -29.87 Thousand USD | -185.44% |
| 2005 Q2 | -10.46 Thousand USD | -1238.74% |
| 2005 Q4 | -21.52 Thousand USD | 27.93% |
| 2004 Q4 | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q1 | 1093.00 USD | 181.75% |
| 2004 Q2 | - USD | -100.0% |
| 2004 FY | - USD | -100.0% |
| 2003 Q3 | 185.00 USD | -87.39% |
| 2003 FY | 1088.00 USD | -91.43% |
| 2003 Q4 | -1337.00 USD | -822.7% |
| 2003 Q1 | 773.00 USD | 809.41% |
| 2003 Q2 | 1467.00 USD | 89.78% |
| 2002 Q3 | 72.00 USD | -93.66% |
| 2002 FY | 12.69 Thousand USD | 0.0% |
| 2002 Q4 | 85.00 USD | 18.06% |
| 2002 Q1 | 11.4 Thousand USD | 0.0% |
| 2002 Q2 | 1136.00 USD | -90.04% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Arch Therapeutics, Inc. | -2439.00 USD | 74.416% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 100.005% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 99.805% |
| Rebus Holdings, Inc. | - USD | Infinity% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 100.001% |
| Qrons Inc. | - USD | Infinity% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 99.998% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 98.707% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 99.498% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 100.004% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | 120.116% |
| Institute of Biomedical Research Corp. | - USD | Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | 100.006% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | 100.949% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 98.173% |
| Mesoblast Limited | -35.16 Million USD | 99.998% |
| Marizyme, Inc. | 457.7 Thousand USD | 100.136% |
| Genus plc | 178.7 Million USD | 100.0% |
| VioQuest Pharmaceuticals, Inc. | - USD | Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 100.0% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | 101.003% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | 100.152% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 94.327% |
| ContraFect Corporation | -154 Thousand USD | 99.595% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 98.752% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | 100.813% |
| IMV Inc. | -962.29 Thousand USD | 99.935% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 99.839% |
| MultiCell Technologies, Inc. | 49.32 USD | 1365.207% |
| ONE Bio Corp. | 20.12 Million USD | 100.003% |
| Accustem Sciences Inc. | - USD | Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 100.002% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | 101.276% |
| Q BioMed Inc. | -8988.00 USD | 93.057% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 100.002% |
| Mosaic ImmunoEngineering Inc. | - USD | Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 95.954% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 100.001% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 99.945% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | 100.891% |
| GlobeStar Therapeutics Corporation | - USD | Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 87.399% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | 100.444% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 99.36% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 99.275% |
| HST Global, Inc. | - USD | Infinity% |
| CSL Limited | 7.56 Billion USD | 100.0% |
| Wesana Health Holdings Inc. | - USD | Infinity% |
| Halberd Corporation | -208.00 USD | -200.0% |
| Enzolytics Inc. | 30.7 Thousand USD | 102.032% |
| Agentix Corp. | - USD | Infinity% |
| Resverlogix Corp. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | 100.129% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | 1.1 Billion USD | 100.0% |
| Enzon Pharmaceuticals, Inc. | - USD | Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 99.879% |
| RespireRx Pharmaceuticals Inc. | - USD | Infinity% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | 100.101% |
| Zenith Capital Corp. | - USD | Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 100.0% |
| Ember Therapeutics, Inc. | - USD | Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 92.954% |
| WPD Pharmaceuticals Inc. | - USD | Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 99.256% |
| Kadimastem Ltd | -630.13 Thousand USD | 99.901% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 100.063% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 100.006% |
| BioStem Technologies, Inc. | 15.42 Million USD | 100.004% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | - USD | Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 94.728% |
| Cell Source, Inc. | - USD | Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 100.353% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 100.353% |
| NovAccess Global Inc. | - USD | Infinity% |
| Affymax, Inc. | 1.35 Million USD | 100.046% |
| Itoco Inc. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | - USD | Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | Infinity% |
| Mobile Lads Corp. | - USD | Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 97.848% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | - USD | Infinity% |
| NanoSphere Health Sciences Inc. | - USD | Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | 100.139% |
| SYBLEU INC | 11.69 Thousand USD | 105.335% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 100.014% |
| Bioxytran, Inc. | -8285.00 USD | 92.468% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | - USD | Infinity% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | - USD | Infinity% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | - USD | Infinity% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | - USD | Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 99.833% |
| Neutra Corp. | 14.33 Thousand USD | 104.353% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 99.239% |
| PureTech Health plc | -1.6 Million USD | 99.961% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 99.938% |
| IXICO plc | 3.27 Million USD | 100.019% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 99.91% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 99.965% |
| CSL Limited | 7.7 Billion USD | 100.0% |
| Cellectis S.A. | 18 Thousand USD | 103.467% |